Wall Street Zen upgraded shares of Aveanna Healthcare (NASDAQ:AVAH – Free Report) from a buy rating to a strong-buy rating in a research note published on Saturday,Wall Street Zen reports.
Other equities research analysts have also issued reports about the stock. Weiss Ratings upgraded shares of Aveanna Healthcare from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 14th. Royal Bank Of Canada reissued an “outperform” rating on shares of Aveanna Healthcare in a research note on Friday. Barclays lifted their price objective on Aveanna Healthcare from $9.50 to $15.00 and gave the stock an “overweight” rating in a research report on Friday, August 28th. UBS Group upped their target price on Aveanna Healthcare from $8.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Finally, BMO Capital Markets upped their target price on Aveanna Healthcare from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Aveanna Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $14.25.
View Our Latest Stock Analysis on AVAH
Aveanna Healthcare Price Performance
Aveanna Healthcare (NASDAQ:AVAH – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.02. The business had revenue of $695.54 million for the quarter, compared to analysts’ expectations of $679.48 million. Aveanna Healthcare had a return on equity of 70.01% and a net margin of 11.44%. On average, equities analysts predict that Aveanna Healthcare will post 0.77 EPS for the current year.
Insiders Place Their Bets
In related news, major shareholder Paul R. Vigano sold 14,500,002 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $11.50, for a total transaction of $166,750,023.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder J.H. Whitney Equity Partners V sold 12,496,077 shares of Aveanna Healthcare stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $11.50, for a total transaction of $143,704,885.50. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 48,566,081 shares of company stock valued at $558,509,932. 5.30% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Aveanna Healthcare
Hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of Aveanna Healthcare in the second quarter valued at $63,504,000. Marshall Wace LLP purchased a new position in Aveanna Healthcare during the third quarter worth about $59,731,000. Boston Partners lifted its position in Aveanna Healthcare by 5.4% during the third quarter. Boston Partners now owns 3,024,899 shares of the company’s stock worth $37,450,000 after buying an additional 153,920 shares during the period. Braidwell LP boosted its stake in Aveanna Healthcare by 39.1% in the 2nd quarter. Braidwell LP now owns 3,065,106 shares of the company’s stock worth $26,268,000 after buying an additional 861,600 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in Aveanna Healthcare by 110.3% in the 3rd quarter. First Trust Advisors LP now owns 1,401,516 shares of the company’s stock worth $17,393,000 after buying an additional 735,090 shares during the last quarter. Institutional investors and hedge funds own 87.96% of the company’s stock.
Trending Headlines about Aveanna Healthcare
Investors following AVAH have been watching these headlines:
- Positive Sentiment: Third-quarter adjusted earnings were $0.23 per share, above the $0.21 consensus and up from $0.15 a year earlier. Revenue of $695.54 million also topped estimates of $679.48 million. Aveanna Healthcare Q3 Earnings and Revenues Beat Estimates
- Positive Sentiment: Aveanna raised its 2026 guidance; its revenue outlook is $2.7 billion, broadly in line with consensus. Investors may also see potential support from growth and operational efficiencies, as well as a planned California rate increase in 2027. Aveanna Healthcare: Revenue Growth, Guidance Raises, Yet Shares Still Trade At A Discount
- Negative Sentiment: Aveanna reported goodwill, intangible and other long-lived asset impairment for the quarter. Separately, an analysis notes that leverage and exposure to Medicaid remain investor concerns despite the company’s growth and valuation discount. Aveanna Reports Asset Impairment
Aveanna Healthcare Company Profile
Aveanna Healthcare Holdings Inc. is a U.S. provider of home-based healthcare services for children and adults with complex medical needs. Its services include private-duty nursing and personal care, home health nursing and therapy, and hospice care, helping patients receive support in their homes and communities. The company also provides medical supplies and related services, including products used for enteral nutrition. Aveanna serves patients and families across multiple states through a network of clinicians, caregivers, and local operations.
Further Reading
- Five stocks we like better than Aveanna Healthcare
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Aveanna Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aveanna Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
